MEK1/2 inhibitor ATR-002 reverses SARS-CoV-2-induced immune gene upregulation in lung cells
Background
Severe SARS-CoV-2 infections often lead to hospitalization due to a systemic inflammatory response, cytokine imbalance, and acute respiratory distress syndrome (ARDS). Direct-acting antivirals have limited treatment windows, shifting focus to host-targeted therapies. The Raf/MEK/ERK signaling cascade, particularly MEK1/2, has emerged as a promising target for both antiviral and anti-inflammatory interventions. While a Phase II trial showed efficacy for the MEK1/2 inhibitor ATR-002 in hospitalized COVID-19 patients, its comprehensive anti-inflammatory mechanism, beyond a few candidate cytokines, remained underexplored.
Study Design
Researchers conducted a comprehensive transcriptome analysis on SARS-CoV-2-infected Calu-3 lung cells treated with or without the MEK1/2 inhibitor ATR-002. The primary endpoint was to identify transcriptional effects on immune regulatory genes. To distinguish between effects due to reduced viral load versus direct pathway interference, MEK1/2 inhibition was also tested in a non-infectious scenario. Gene expression was assessed using transcriptome analysis to provide a broad overview of changes.
Results
Gene expression data revealed a significant upregulation of innate immune-response-related genes in SARS-CoV-2-infected cells. These included cytokines such as CXCL10 and CCL5, which are often associated with severe COVID-19 cases, and interferon-stimulated genes (ISGs) like MX1 and OASL. ATR-002 effectively reversed this infection-induced upregulation across numerous genes. While some of this reversal was linked to impaired viral replication, the study also identified direct modulation of specific immune regulatory genes by MEK1/2 inhibition itself, independent of viral load reduction. > NLRP1 expression was newly identified as a direct target of MEK1/2 inhibition, alongside EGR1 and IFNL1, demonstrating a direct role in modulating innate immunity via the Raf/MEK/ERK axis. This suggests a dual mechanism of action for ATR-002, impacting both viral replication and host immune responses.
Key Findings
- SARS-CoV-2 infection significantly upregulated innate immune-response genes like
CXCL10,CCL5,MX1, andOASLin Calu-3 cells. - MEK1/2 inhibitor ATR-002 reversed the upregulation of these immune regulatory genes in infected cells.
- Some gene expression changes were due to ATR-002's effect on viral replication, but others were direct pathway interference.
EGR1,IFNL1, andNLRP1were identified as directly modulated by MEK1/2 inhibition, linking to innate immunity.NLRP1expression was newly identified as a specific target of MEK1/2 inhibition.
Why It Matters
This study provides crucial insights into the anti-inflammatory mechanisms of ATR-002, a MEK1/2 inhibitor already in Phase II clinical trials for COVID-19. It suggests that ATR-002's benefits extend beyond merely reducing viral load, directly modulating host innate immune responses by targeting genes like NLRP1. This strengthens the rationale for host-targeted therapies in COVID-19, particularly for managing the hyper-inflammatory phase where direct antivirals are less effective. Understanding these specific gene modulations could inform future therapeutic strategies, potentially leading to more refined protocols for combining ATR-002 with other treatments to mitigate severe inflammatory outcomes.
atr-002
mek1-2-inhibitor
sars-cov-2
covid-19
innate-immunity
transcriptomics